ALPMF - Kiniksa Positive COVID-19 Data And Other News: The Good Bad And Ugly Of Biopharma
Kiniksa Reports Positive Outcome from 28-Day Clinical Trial
Kiniksa Pharmaceuticals Ltd. (KNSA) announced that it has received positive data from its COVID-19 treatment trial. This 28 day clinical outcomes data pertains to the open label treatment protocol with mavrilimumab. The company also announced an active IND with the FDA for its global placebo-controlled Phase 2/3 clinical trial of mavrilimumab for treating severe COVID-19 pneumonia and hyperinflammation.
The treatment protocol involved 13 non-mechanically ventilated patients suffering from severe COVID-19 pneumonia and hyperinflammation. The patients were given a single intravenous dose of mavrilimumab 6 mg/kg